AFA-281
/ AfaSci
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
October 22, 2025
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Completed | Sponsor: Afasci Inc | Recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ May 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2024
Trial completion • Trial completion date • Trial primary completion date • Neuralgia • Pain
June 27, 2025
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=58 | Recruiting | Sponsor: Afasci Inc | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Aug 2025
Trial completion date • Trial primary completion date • Neuralgia • Pain
June 27, 2025
AFA-281-202: Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain
(clinicaltrials.gov)
- P2 | N=408 | Not yet recruiting | Sponsor: Afasci Inc | Trial completion date: Jul 2030 ➔ Mar 2032 | Initiation date: Aug 2026 ➔ Apr 2027 | Trial primary completion date: Jul 2030 ➔ Mar 2032
Trial completion date • Trial initiation date • Trial primary completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain
December 06, 2024
A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Afasci Inc
New P1 trial • Addiction (Opioid and Alcohol)
November 29, 2024
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
(clinicaltrials.gov)
- P2 | N=36 | Not yet recruiting | Sponsor: Afasci Inc
New P2 trial • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry • Sleep Disorder
October 21, 2024
Efficacy Study With AFA-281 for the Treatment of Back Pain
(clinicaltrials.gov)
- P2 | N=372 | Not yet recruiting | Sponsor: Afasci Inc
New P2 trial • Back Pain • Musculoskeletal Pain • Pain
October 09, 2024
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=58 | Recruiting | Sponsor: Afasci Inc | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2024
Trial completion date • Trial primary completion date • Neuralgia • Pain
August 01, 2023
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Afasci Inc | Trial completion date: Dec 2024 ➔ Sep 2024 | Trial primary completion date: Oct 2023 ➔ Aug 2024
Trial completion date • Trial primary completion date • Neuralgia • Pain
July 20, 2023
Single Ascending Dose and 14-day Study With AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Afasci Inc | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2023 ➔ Apr 2023
Enrollment open • Trial initiation date • Neuralgia • Pain
September 21, 2022
Single Ascending Dose and 14-day Study With AFA-281 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Afasci Inc
New P1 trial • Neuralgia • Pain
1 to 10
Of
10
Go to page
1